NICE approves capsule sponge test for oesophageal cancer in primary care

Getty Images

NICE has approved the use of a capsule sponge test to detect oesophageal cancer and Barrett’s oesophagus in primary care and community settings.

Two tests – Cytosponge and EndoSign – have been recommended for use on the NHS under new draft guidance.

Patients swallow a small capsule on a string which dissolves in the stomach leaving a sponge which expands over about seven minutes and then is then pulled out collecting cells from the lining of the oesophagus.

Under the recommendations, as options for detecting Barrett’s oesophagus and oesophageal cancer in people with persistent gastro-oesophageal reflux disease and multiple risk factors who do not need an urgent suspected cancer pathway referral.

People whose test results indicate possible cancer or Barrett’s oesophagus should then be referred for further investigation with endoscopy.

The tests, which cost around £100, can also be used as monitoring tool in people already diagnosed with Barrett’s oesophagus to periodically check for cellular changes that may indicate oesophageal cancer, NICE said.

It follows a series of pilot schemes of the technology, which does not require sedation and so can be done in GP practices and community diagnostic centres.

One NHS study of EndoSign of 2,000 high risk patients was done in GP surgeries and diagnostic hubs across the East of England, Lancashire and South Cumbria, and Wessex Cancer Alliance.

The committee reviewing the evidence said technologies will help reduce high demand on NHS endoscopy services.

In addition, in some parts of the NHS, people with Barrett’s oesophagus are not being checked as often as current guidance recommends.

The test can be administered by one healthcare professional after specialist training.

Studies have shown that 95 out of every 100 people are able to swallow the capsule successfully after one or more attempts.

The recommendations are the first to be produced through the National HealthTech Access Programme to identify high-impact medical technologies that can be made available around the country.

Professor Jonathan Benger, chief executive of NICE said: ‘Oesophageal cancer is very difficult to treat when it is diagnosed at a later stage, so identifying people sooner is really important.

‘Capsule sponge tests offer a quick and less invasive way to detect concerning changes associated with oesophageal cancer or Barrett’s oesophagus, helping to identify people who should go on to have further tests and treatment.

‘This new technology has the potential to make testing easier for patients, while helping the NHS focus valuable endoscopy capacity on those who need it most.’

Thomas Slater, director of HealthTech at NICE, said the recommendations were a real example of what they wanted to achieve for patients and the NHS.

‘Capsule sponge tests show how innovative health technologies can improve people’s experience of care and help the NHS use its resources more effectively.’

Professor Peter Johnson, national clinical director for cancer at NHS England, added: ‘Many people have acid reflux, and having an easier way to check for changes in the lining of the oesophagus can make a big difference for patients – reducing the need for more complicated endoscopy tests and helping the NHS free up resources to find cancers at an earlier stage.’

A consultation on the draft guidance will run until 7 December 2026.